This page is dedicated to Roche’s response to the Coronavirus disease (COVID-19) outbreak. On March 12, Roche was granted FDA Emergency Use Authorization (EUA) on cobas® SARS-CoV-2 Test in response to COVID-19. In addition, Roche is closely monitoring the situation and the potential global and local impacts on our product supply. We will continue to work diligently to ensure we provide you with the most current information.
As the world watches the magnitude of the COVID-19 pandemic unfold, we continue to actively manage our supply chain and are taking measures to maximize operations and employee safety.
We have activated our Business Continuity Management (BCM) plan, which includes a broad range of emergency measures that enable us to increase both our short-term and long-term capacity. Our task force meets daily.
Our manufacturing network has a global footprint with Roche plants located in China, Switzerland, Germany, South Africa and the United States. Our manufacturing site in China opened very recently and does not produce for the U.S. market, so its operations have no impact on supply in this country. Importantly, all of our manufacturing sites have detailed business continuity plans and we will execute those plans as needed in response to regional outbreaks.
Roche business continuity plans address potential risks across multiple categories that include:
U.S. Product Supply Updates
Increased demand for COVID-19 testing materials and the cobas Liat - as it relates to seasonal influenza testing - has been especially dramatic. Non-COVID-19 related product demand remains at standard levels, allowing us to better meet routine testing needs. We have increased stock levels in our broad portfolio (tissue, serum work area, point of care and molecular products) to support the continuity of supply should we face a disruption associated with the pandemic.
U.S. Service and Support Update
Our focus remains to keep customers up and running. This guiding principle drives us to prioritize our emergency service repair work. It also informs installs and planned service activities. We deploy our support personnel based on these prioritization guidelines:
Our task force meets daily to ensure rapid response to emerging crisis topics that may impact support. Our current strategies are intended to keep our employees safe, optimize our service and keep our customers in operation include:
We will continue to provide any updates in real time. Throughout this public health crisis, one thing is clear – the role of the lab has never been more vital.
cobas® SARS-CoV-2 Test (for the COVID-19 Coronavirus)
Qualitative assay for use on the cobas® 6800/8800 Systems
For use under the Emergency Use Authorization (EUA) only
For in vitro diagnostic use